BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV MYNZ (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announced that Bill Caragol, the Company’s CFO, will present and lead one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, which takes place from March 22nd to 23rd, 2023.

The presentation begins March 22, 2023 at 12:15 p.m. ET and can be viewed live here:
https://sidoti.zoom.us/webinar/register/WN_apzthw9PRlOrUq5PSD5Dcw.

Mainz Biomed will also host virtual one-on-one meetings with investors on Wednesday and Thursday, March 22 and 23, 2023. To register for the presentation or one-on-one sessions, visit www.sidoti.com/events. Registration is free and you do not have to be a Sidoti customer.

About Sidoti & Company
For over two decades Sidoti & Company (http://www.sidoti.com) is a leading provider of independent securities research that focuses specifically on small and microcap companies and institutions that invest in their securities, with most of its coverage in the $100 million to $5 billion market capitalization range. The firm’s approach offers corporate and institutional clients a combination of high quality research, nationwide sales efforts focused on small and micro caps, broad access to corporate management teams and comprehensive trading support. Sidoti serves more than 500 institutional clients in North America.

About ColoAlert
ColoAlert, Mainz Biomed’s flagship product, offers high sensitivity and specificity in an easy-to-use, at-home colorectal cancer screening kit. This non-invasive test can indicate tumors by analyzing tumor DNA and offers better early detection than fecal occult blood (FOBT) tests. Based on PCR technology, ColoAlert detects more cases of colorectal cancer than other stool tests, enabling earlier diagnosis (Gies et al., 2018). The product is commercially available in selected EU countries through a network…